Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis
Makoto Chuma(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital), Taito Fukushima(Kanagawa Prefectural Hospital Organization), Joji Tani(Kagawa University), Hisashi Hidaka(Kitasato University), Hiroshi Shibata(Social Insurance Saitama Chuo Hospital), Kazuya Kariyama(Okayama Prefecture), Satoshi Moriya(Yokohama City University Medical Center), Hidenori Toyoda(Ogaki Municipal Hospital), Nobuhiro Hattori(St. Marianna University School of Medicine), Kazuhiro Nouso(Okayama Prefecture), Kazushi Numata(Yokohama City University Medical Center), Satoshi Kobayashi(Kanagawa Cancer Center), Atsushi Hiraoka(Ehime Prefectural Central Hospital), Takashi Kumada(Gifu Kyoritsu University), Shinya Fukunishi(Osaka Medical and Pharmaceutical University), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Ei Itobayashi(Asahi General Hospital), Kazuto Tajiri(Toyama University Hospital), Naohisa Wada(Kitasato University), Toshifumi Tada(Himeji Red Cross Hospital), Shuitirou Iwasaki(Kitasato University), Toru Ishikawa(Saiseikai Niigata Daini Hospital), Shunji Hirose(Tokai University), Masanori Atsukawa(Nippon Medical School), Haruki Uojima(National Center for Global Health and Medicine), Tsunamasa Watanabe(St. Marianna University School of Medicine), Michitaka Imai(Saiseikai Niigata Daini Hospital), Michiie Sakamoto(Keio University), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Tatehiro Kagawa(Tokai University), Satoshi Yasuda(Ogaki Municipal Hospital), Shogo Iwabuchi(Jikei University School of Medicine), Hideko Ohama(Osaka Medical and Pharmaceutical University), Shinichiro Nakamura(Himeji Red Cross Hospital), Norio Itokawa(Chiba Hokusou Hospital)
Cited by 38
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625